Unknown

Dataset Information

0

Mycotic Antimicrobial Localized Injection: A Randomized Clinical Trial Evaluating Intrastromal Injection of Voriconazole.


ABSTRACT: PURPOSE:To determine if there is a benefit to adjuvant intrastromal voriconazole (ISV) injections for primary treatment of filamentous fungal keratitis. DESIGN:Outcome-masked, randomized controlled clinical trial. PARTICIPANTS:Patients with moderate vision loss resulting from a smear-positive fungal ulcer. METHODS:Study eyes were randomized to topical natamycin plus ISV injection versus topical natamycin alone. MAIN OUTCOME MEASURES:The primary outcome of the trial was microbiological cure on 3-day repeat culture analysis. Secondary outcomes included microbiological cure on 7-day repeat culture analysis; 3-week and 3-month best spectacle-corrected visual acuity; infiltrate or scar size or both; rate of perforation; therapeutic penetrating keratoplasty (TPK); and other adverse events. RESULTS:A total of 151 patients with smear-positive ulcers were screened and 70 were enrolled at Aravind Eye Hospital, Pondicherry, India. Baseline cultures grew Fusarium in 19 samples (27%), Aspergillus in 17 samples (24%), and other filamentous fungi in 19 samples (27%) and showed negative results in 13 samples (19%). Those randomized to ISV injection had 1.82 times the odds of 3-day culture positivity after controlling for baseline culture status (95% confidence interval [CI], 0.65-5.23; P = 0.26, bias-corrected logistic regression) and 1.98 times the odds of positive 7-day culture results, after controlling for baseline culture status (95% CI, 0.69-5.91; P = 0.20, bias-corrected logistic regression). Those randomized to ISV injection showed 0.5 logMAR lines (approximately 0.5 Snellen lines) of decreased visual acuity (95% CI, -2.6 to 3.6 lines; P = 0.75) and 0.55 mm worse infiltrate or scar size or both at 3 months after controlling for baseline values (95% CI, -0.13 to 1.25; P = 0.11). Intrastromal voriconazole injections showed a 2.85-fold increased hazard of perforation after controlling for baseline infiltrate depth (95% CI, 0.76-10.75; P = 0.12) but no difference in the rate of TPK (hazard ratio, 0.95; 95% CI, 0.44-2.04; P = 0.90). CONCLUSIONS:There seems to be no benefit to adding ISV injections to topical natamycin in the primary treatment of moderate to severe filamentous fungal ulcers. Studies consistently suggest that voriconazole has a limited role in the treatment of filamentous fungal ulcers.

SUBMITTER: Narayana S 

PROVIDER: S-EPMC6646068 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Mycotic Antimicrobial Localized Injection: A Randomized Clinical Trial Evaluating Intrastromal Injection of Voriconazole.

Narayana Shivananda S   Krishnan Tiruvengada T   Ramakrishnan Seema S   Samantaray Puja Prativa PP   Austin Ariana A   Pickel Julia J   Porco Travis T   Lietman Tom T   Rose-Nussbaumer Jennifer J  

Ophthalmology 20190320 8


<h4>Purpose</h4>To determine if there is a benefit to adjuvant intrastromal voriconazole (ISV) injections for primary treatment of filamentous fungal keratitis.<h4>Design</h4>Outcome-masked, randomized controlled clinical trial.<h4>Participants</h4>Patients with moderate vision loss resulting from a smear-positive fungal ulcer.<h4>Methods</h4>Study eyes were randomized to topical natamycin plus ISV injection versus topical natamycin alone.<h4>Main outcome measures</h4>The primary outcome of the  ...[more]

Similar Datasets

| S-EPMC3769211 | biostudies-literature
| S-EPMC4962866 | biostudies-literature
| S-EPMC3706180 | biostudies-literature
| S-EPMC8082977 | biostudies-literature